Company intelligence / Profile preview
Pharosgen
South Koreapharosgen.co.kr ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Pharosgen is advancing two lead programs: MPD-1 (PGP2113), a peptide-drug conjugate in Phase 1 for advanced solid tumors characterized by PTEN loss and KRAS mutation, and TNT-ADC, an antibody-drug conjugate targeting cancer and new vascular endothelial cells. MPD-1 uniquely combines with serum albumin for targeted delivery and utilizes a prodrug activated by caspase-3/7 to enable bystander killing effect, aiming to overcome tumor heterogeneity.
- Therapeutic areas
- Oncology
- Modalities
- Peptide-drug conjugateAntibody-drug conjugate
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Seoul National University College of PharmacyUlsan National UniversityKorea Institute of Science and Technology (KIST)
Beyond the preview
Go deeper on Pharosgen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pharosgen.